Trials / Unknown
UnknownNCT05910710
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer. (Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS) | Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation |
Timeline
- Start date
- 2023-03-02
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-06-20
- Last updated
- 2023-06-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05910710. Inclusion in this directory is not an endorsement.